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Abstract
After completion of a number of large scale Genome-Wide Association Studies (GWAS), 
there is still a significant amount of trait and disease variance that cannot be explained by 
existing  genetic  variability.  This  review  introduces  new,  Integrative  Network-based 
Association Study (INAS) approaches that aim to minimize the impact  from multiple 
hypothesis testing statistics,  thus allowing the identification of rare variants/alterations 
and epistatic  interactions.  In  particular  we discuss  methods  that  rely  on  the  de  novo 
computational,  experimental,  and  integrative  dissection  of  context  specific  molecular 
interaction networks (or interactomes, for short). We provide several examples of how 
these  approaches  may  be  used  to  tackle  discovery  of  genetic  variants  and  somatic 
alterations causally related to the presentation of specific traits  and diseases. We also 
discuss how more complex systems, including a variety of non-cell-autonomous traits 
and  diseases  will  require  new  multicellular  networks  that  explicitly  represent  short 
distance paracrine and long distance endocrine interactions.
Introduction
Over the last ten years, the genome wide study of both heritable and somatic  human 
variability  has  gone  from  a  theoretical  concept  to  a  broadly  implemented,  practical 
reality,  covering  the  entire  spectrum  of  human  diseases:  from  cancer  to  obesity  to 
neurodegenerative disorders.  While a number of exciting findings have emerged from 
these studies1, the result of such genome wide association studies (GWAS) has been for 
the most part sobering. For instance, although several genes displaying medium to high 
penetrance  within  heritable  traits  have  been  inferred  by  these  approaches  for  certain 
conditions, other diseases are still missing identification of much of the genetic risk2-7, 
and  few  epistatic  interactions  or  low  penetrance  genes  have  been  identified  due  to 
impractical  requirements  for  cohort  sizes8 as  well  as  a  lack  of  methodological 
developments  that  maximize  power  for  such  detections9.  At  the  other  end  of  the 
spectrum, the extensive somatic genomic rearrangements observed in solid tumors10 yield 
such a broad range of candidate alterations that distinguishing ‘driver’ from ‘passenger’ 
alterations is difficult. 
This begs the question of whether, in a post-GWAS era, existing GWAS datasets 
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may still hold a trove of hidden value. It has been suggested, for instance, that GWAS 
data could be more insightful when studied integratively within the context of other data 
modalities. Indeed, a number of previous studies have integrated significant genotype-
phenotype associations with databases of gene annotations, such as the Gene Ontology11, 
MSigDB12,  or  the  Kyoto  Encyclopedia  of  Genes  and  Genomes13.  The  goal  of  these 
studies is to recognize higher-order structure within the data through aggregation of loci 
that encode genes with similar functions or that are in the same pathway.
A particularly important framework for the integration of genomic, metabonomic, 
and proteomic data is provided by the context-specific networks of molecular interactions 
that determine cell behavior. The basic hypothesis is straightforward. Among the entire 
spectrum of  genetic  and  epigenetic  variants,  those  contributing  to  a  specific  trait  or 
disease  must  have  some  broad  coalescent  properties,  allowing  their  effect  to  be 
functionally canalized via the cell regulatory machinery or via the cell-communication 
machinery  that  allows  distinct  cell  types  to  interact.  Thus,  if  a  comprehensive  and 
accurate map of all  intra and inter-cellular molecular interactions were available,  then 
genetic  and  epigenetic  events  implicated  in  a  specific  trait  or  disease  should  cluster 
within sets of closely interacting genes, within the cell’s regulatory network.
Two approaches are then possible. First, if the regulatory networks determining 
the cell  pathophysiological  behavior  were known  a priori,  e.g.  a canonical  cancer  or 
functional pathway, one could systematically reduce the number of statistical tests for 
association between genetic or epigenetic variations and the trait or disease of interest by 
considering only events that form significant clusters within regulatory networks. This is 
because events that are closer in the regulatory topology of the cell are more likely to 
produce related phenotypic effects.  Such a Pathway-Wide Association Study (PWAS) 
strategy14 may  improve  our  ability  to  distinguish  signals  from  background  noise  by 
mitigating the magnitude of the multiple  hypothesis  testing correction.  In most cases, 
unfortunately, the set of molecular interactions or pathways necessary to present a trait or 
a disease-related phenotype are not well characterized at the molecular level. Indeed the 
entire classical notion of relatively linear and interpretable disease pathways may need to 
be revisited in light of the dynamic, multi-scale, and context-specific complexity of gene 
regulatory networks. Thus, a second approach requires the simultaneous reconstruction of 
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both  context-specific  (and  possibly  multi-cell)  gene  regulatory  networks  and  of  the 
genetic and epigenetic events they harbor. We shall call this second strategy Integrative 
Network-based  Association  Studies  or  INAS  and  suggest  that  INAS  will  become 
increasingly dominant as the dynamic and cell-context specific nature of gene regulatory 
networks is further elucidated.
In this perspective, we explore current advances in PWAS and INAS research, the 
natural corollaries of a regulatory-network-oriented view of traits and disease, and future 
directions that are being pursued within the emerging community of Systems Genetics. 
We will explore how networks (and pathway motifs within them) can be reconstructed 
and validated and how they may provide a valuable integrative framework to interpret 
GWAS as well as other genetic and epigenetic variability data.
THIS IS NOT MY BEAUTIFUL PATHWAY 
An increasing  body  of  evidence  suggests  that  canonical  pathways  may  be  woefully 
inadequate  to  represent  and  model  the  complex  interplay  of  signal  transduction, 
transcriptional, post-transcriptional, metabolic, and other regulatory events that ultimately 
determines  cellular  behavior.  Rather,  they  satisfy  our  need  to  interpret  biological 
Figure 1a: FOXM1 and MYB co-regulation network 
from the Human B Cell Interactome15. Red and blue 
represents  gene  over  and  under  expression, 
respectively, in germinal centers. Blue arcs represent 
protein-protein interactions.
Figure 1b.  Visualization  of  the  signalome-
transfactome molecular interaction network in human 
B cells16. 
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phenomena as linear chains of events or other simple pathway models that can be easily 
visually  interpreted.  Unfortunately,  this  is  a  dramatic  oversimplification.  Biological 
processes and their regulatory control are anything but linear and cellular processes are 
determined  by  complex,  multivariate  interactions  that  cannot  be  visually  interpreted. 
Both require the power of computational modeling to yield valuable biological insight. 
For instance, it has been shown that individual transcription factors regulate hundreds to 
thousands of highly cell-context dependent target genes. Indeed, functional specificity is 
achieved opportunistically by combinatorial interactions between multiple transcription 
factors. For instance, while FOXM1 and MYB individually regulate transcription of more 
than  a  thousand  distinct  genes,  the  about  roughly  100  targets  they  co-regulate  are 
exquisitely  specific  to  human B cells  during  germinal  center  formation,  see  Fig.  1a. 
Conversely, those regulated by either one independently have a wide range of functions 
and are not specifically differentially expressed15. Similarly, transcription factor activity 
is modulated by hundreds of signal transduction proteins16, whose availability is again 
context specific. Fig. 1b, for instance, shows a map of all transcription factors and of their 
computationally  inferred  upstream  modulators  in  a  human  B  cell.  Many  of  these 
interactions have been experimentally validated with low false positive rates, indicating 
that such a level of complexity is realistic. Additionally, recent large-scale screens for 
protein-protein  interactions  in  human  cells20 suggest  that  their  number  are  orders  of 
magnitude  larger  than the few thousand captured  in canonical  pathways.  Clearly,  the 
concept of a relatively small number of hierarchical and relatively independent signal 
transduction pathways is not reconcilable  with these observations.  Finally,  adding yet 
another level of complexity,  causal dependencies between the genetic,  regulatory,  and 
functional  layers  provide  insight  into  the  mechanisms  by  which  rare  germline  allele 
variants and somatic alterations may 
impact  the  activity  of  entire 
constellations  of  transcription 
factors,  which  in  turn  regulate 
thousands of genes , see Fig. 2.
As  discussed,  such  intrinsic 
complexity  is  made  even  more 
Figure 2. Genetic subnetwork controlled by  Zfp90 (black 
node) as a central node in the liver transcriptional network. 
This subnetwork was obtained from a full liver expression 
network by identifying all nodes that were descended from 
and within a path length of 3 of the  Zfp90 node. Nodes 
highlighted in green represent genes testing as causal for 
fat mass. 
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daunting by the exquisite cell-context specific nature of the cell regulatory machinery. In 
other words, what we learn in one cellular phenotype may not hold true for another. For 
instance,  it  is well  known that the oncogenic nature of genetic lesions is cell  context 
specific and that depending on the microenvironment signals specific lesions in the same 
cell  may or may not be tumorigenic27.  Indeed, the paracrine and endocrine molecular 
interactions that allow distinct cell types and even whole organs to communicate form the 
highest  order networks in a  living organism that  directly  define its  physiological  and 
pathological states.  Thus, while canonical pathways may provide useful conceptual tools, 
they cannot recapitulate the full complexity of cellular regulation. To be truly predictive 
and informative, cellular networks must be reconstructed  de novo  within each cellular 
phenotype context of interest.  Further, we can distinguish between cell autonomous and 
non cell autonomous processes in thinking about more predictive biological networks. 
Whereas cancer may make a reasonably good cell autonomous system (given when you 
profile cancer you get both stroma and cancer at the same time), common non-cancer 
human diseases like obesity and type II diabetes can result from a failure in multiple 
organ systems including the central nervous system and tissues involved in partitioning 
and disposal of nutrients, and so may be best modeled as a non-cell autonomous system. 
In  fact,  we  have  shown  that  interaction  networks  constructed  between  tissues  like 
hypothalamus  and  adipose  tissue  collected  from  an  experimental  cross  population 
segregating obesity and type II diabetes, may be specific to cross tissue interactions28. 
That is, some subnetworks identified in cross-tissue interaction networks are not visible 
within  single  tissue  networks,  exhibiting  a  degree  of  regulation  that  may go beyond 
simple cell  autonomous systems.  Molecular  networks constructed from heterogeneous 
tissues  have  also  exhibited  extraordinary  context  sensitivity,  with  interactions  among 
different cell types making up a given organ specific to functions associated with that 
organ. In a model for type II diabetes, molecular interactions between different tissues 
were observed to be more abundant than interactions within any given tissue (or cell 
type)29, and insulin signaling in osteoblasts has been shown to be necessary for whole-
body glucose homeostasis30.  These examples highlight that molecular networks capable 
of predicting whole system behavior will require modeling approaches that go beyond 
cellular networks, requiring the explicit representation of interactions at a hierarchy of 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
11
.5
73
2.
1 
: P
os
te
d 
24
 F
eb
 2
01
1
scales that provide a path to define the molecular interactions that define physiological 
states related to disease phenotypes31.  
REVERSE ENGINEERING CELLULAR NETWORKS 
Just a few years ago, determining and experimentally validating a single kinase substrate 
or transcription factor target required a year or more of bench work. Since regulatory and 
protein-complex  networks  in  eukaryotes  appear  to  be  highly  complex  –hundreds  of 
thousands  of  interactions,  –  context-specific34,  and  dynamic,  how  can  one  possibly 
reconstruct them in sufficient depth and with sufficient accuracy? Indeed, imagine having 
not only to elucidate hundreds of thousands of these interactions but also having to assess 
how they  may  change  and  reorganize  themselves,  under  multivariate  control,  within 
distinct cellular phenotypes and possibly under distinct stimuli.  It is precisely out of this 
necessity  that  the  fields  of  high-throughput  computational  and  experimental  reverse 
engineering  have  blossomed.  This  is  an  important  and timely  effort.  Ultimately,  our 
success  in elucidating  disease related  mechanisms on a  rational,  predictive  basis  will 
depend  on  our  ability  to  use  stochastic  and  kinetic  models  to  accurately  map  cell 
regulatory networks and to predict their response to pathophysiological stimuli.  
On  the  experimental  side,  large-scale,  high-throughput  efforts  have  started  to 
release enormous amounts of raw data over the last five years. These data can be used as 
a  scaffold  for  the  assembly  of  entire  regulatory  and  protein-complex  networks,  thus 
providing insight  into the architecture  of  the  cell  in  terms of  how direct  interactions 
between molecules may allow assembly of protein complexes, transduction of signals, 
and  control  of  the  transcriptional  machinery  of  the  cell37.  For  example,  networks  of 
protein–protein interactions in human cells have been assembled using yeast two-hybrid 
(Y2H) technology or tandem affinity purification coupled with mass spectrometry (TAP–
MS)20.  Similarly,  candidate  transcriptional  targets  of  specific  transcription  factors 
(protein–DNA  interactions)  have  been  mapped  using  the  techniques  of  chromatin 
immunoprecipitation coupled with DNA microchips (ChIP–chip)38  or sequencing (ChIP–
PET)39, DNA adenine methylase identification (DamID)40, or yeast one-hybrid assays41. 
Physical interactions can also be measured in vitro using DNA or protein arrays, which 
have  been  used  to  identify  transcription  factor  binding  sites  and  the  substrates  of 
kinases44.  While  interactions  characterized  by  high-throughput  experimental  methods 
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generally have high false positives and false negative rates and are unlikely to generalize 
to cellular contexts other than the one in which they were ascertained, they nonetheless 
provide an initial if sparse snapshot of regulatory networks, especially when integrated 
with other types of data that can help filter the interactions most appropriate to a given 
context25. By mapping and interpreting changes among snapshots in different contexts we 
can begin to create a more comprehensive scaffold.
Complementing  and  extending  high-throughput  experimental  assays, 
computational  reverse-engineering  algorithms  have  recently  achieved  accuracy  and 
sensitivity comparable with their experimental counterpart, at a fraction of their cost and 
time  requirements.  Computational  methods  for  reverse-engineering  cellular  networks 
were first developed for the study of prokaryotes and lower eukaryotes45-47 and have more 
recently  become  highly  successful  in  reconstructing  the  transcriptional32,  post-
translational,  post-transcriptional50,  metabolic51,  and  protein-complex15 logic  of  human 
cells,  as well as of their dependence on the genetic information encoded in the DNA 
molecule, thus paving the road to the regulatory network based study of human disease. 
Among  recent  approaches,  there  has  been  significant  success  in  using  integrative 
approaches to combine both multiple clues as well as multiple layers of regulation within 
cellular networks. 
Computational methods all rely, in one way or another, on measuring changes in 
distinct molecular moieties (e.g., mRNAs, microRNAs, proteins, etc.) as a response to 
either  endogenous  or  exogenous  perturbations.  The  former  include,  for  instance, 
differences in kinetic constants induced by the genotypic variability between different 
individuals or the different spectrum of genetic lesions associated with a particular tumor 
phenotype54.  The  latter  include  small-molecule60,  RNAi,  and  environmental 
perturbations61,  such as differences in temperature,  nutrients,  or culture serum, among 
many  others.  In  fact,  several  methods  have  been  published  that  specifically  use 
perturbations  to  infer  regulatory  networks  or  to  interrogate  them  to  infer  drug 
sensitivity63, resistance64, and mechanism of action. 
Finally,  meta-network information,  highlighting functional  rather  than physical 
interactions,  is  provided  by  genetic  interactions,  which  chart  the  combinatorial 
relationships among genes in control of a common phenotype. Genetic interactions are 
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identified by comparing the phenotypic effect of disrupting (or overexpressing) a gene 
individually to the effect of disrupting two or more genes in combination65. For example, 
‘synthetic sickness’ (or in the extreme ‘synthetic  lethality’)  is a genetic  interaction in 
which disrupting both genes has a far more deleterious effect than expected from either 
disruption alone. ‘Epistasis’ is a genetic interaction in which one gene disruption masks 
the phenotypic effect of the other.  In model organisms such as yeast, large networks of 
genetic interactions are being measured through systematically-applied combinations of 
gene  knockouts66.  In  higher  eukaryotes  including  worms,  flies,  and  humans,  genetic 
interactions are presently being explored through the technique of combinatorial RNAi65 
and other RNAi-based screening approaches67. Importantly, synthetic-sick and epistatic 
interactions  are  also  prevalent  in  GWAS,  in  which  genotypes  at  multiple  loci  come 
together to exert combinatorial control over the phenotypic trait. Alternatively, epistasis 
can occur when one locus with strong individual linkage to the phenotype is modified by 
the presence of another ‘genetic modifier’.  In the absence of prior information, however, 
de-novo identification of epistatic  interactions in GWAS is greatly  limited by lack of 
statistical power, although emerging methods are beginning to address this limitation. 
EXAMPLES OF PWAS AND NBAS APPROACHES
In the following, we discuss several approaches that have been successful in identifying 
genes that are critically involved in the presentation of a phenotype, due to either genetic 
alteration  or  functional  dysregulation.  This  list,  rather  than  being  comprehensive,  is 
intended to illustrate different approaches in both PWAS and NBAS
Canonical Pathway Analysis:  Canonical  pathways are compact  representations of the 
knowledge accumulated in a large number of manuscripts and supported by experimental 
assays  about  the  relationship  between  multiple  proteins,  usually  in  the  context  of  a 
specific biological process, e.g. embryogenesis, apoptosis, or tumorigenesis. While the 
knowledge represented  within  canonical  pathways  is  likely  incomplete  and may lack 
context specificity, it does represent an important collection of molecular interactions that 
have previously resulted in the elucidation of key biological mechanisms.
For instance, integration of NF-κB pathway and targets analysis with GWAS data 
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from a  large  collection  of  Diffuse  Large  B  Cell  Lymphoma  (DLBCL)  samples  was 
successful  in  the  identification  of  this  gene  as  the  key  integrator  of  a  spectrum  of 
upstream genetic  alterations  characterizing  the  more  aggressive  ABC subtype  of  the 
disease from its GCB counterpart71. These included several genes in the BCR and other 
signal  transduction  pathways,  such  as  CARD11,  A20,  TRAF2,  TRAF5,  TAK1,  and 
RANK, among others. Surprisingly, while Nf-κB itself was not genetically altered in the 
ABC subtype, it was shown to constitute a key non-oncogene addiction for ABC-DLBCL 
cells.
There have also been attempts to create more informative pathways by automated 
data-mining of literature data, using machine-learning approaches. These more complex 
and non human-interpretable  networks  have  been used to  cluster  information  coming 
from disease-related human variability data, such as for instance in the study of genetic 
predisposition to several human diseases72. 
Integrative genomics:  There is already a rich literature on methods for using cellular 
networks, including protein-protein and protein-DNA interaction networks, to interpret 
gene expression profiles, with the goal of identifying network “hot spots” or “expression-
activated modules”. Expression-activated modules are sets of proteins enriched for both 
interaction and coexpression across several conditions; they provide an important means 
of distilling the thousands of interactions present in a typical molecular network to arrive 
at  a  smaller  number  of  discrete  modules  of  activity.   As  recent  examples,  DEGAS 
(DysrEgulated  Gene  set  Analysis  via  Subnetworks)  and  IDEA  (Interactome 
Dysregulation Enrichment Analysis) represent methods for identifying connected gene 
subnetworks  significantly  enriched for  genes  that  are  dysregulated  in  specimens  of  a 
disease or following a chemical perturbation. In Parkinson's disease, DEGAS found novel 
evidence for involvement of mRNA splicing, cell proliferation, and the 14-3-3 complex 
in the disease progression, while in B cell lymphoma, IDEA identified genetic alterations 
in Chronic Lympocytic Leukemia and Follicular Lymphoma.
In parallel, a set of related methods have been developed for integration of protein 
networks with the results of genome wide linkage and association studies.  For instance, 
Lage et al.77 searched for protein complexes whose genes were associated with similar 
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phenotypes, using a human protein–protein interaction network integrating both human 
interactions  and  interactions  from  model  organisms.  Proteins  were  ranked  by  the 
phenotype  similarity  score  of  their  associated  diseases  and  of  those  of  their  direct 
network  neighbors.  In  dmGWAS78,  dense  subnetworks  of  protein-protein  interactions 
were  tested  for  the  enrichment  of  genes  harboring  low  p-value  SNPs  from  GWAS 
studies.   Compared  with  other  pathway-based  approaches,  the  method  introduces 
flexibility  in  defining  a  gene  set  through  use  of  local  protein-protein  interaction 
information. 
A similar approach integrated 
a  large-scale  human  protein-protein 
interaction  network  and  a  set  of 
genes linked to ataxia to demonstrate 
a potential gain in statistical power37. 
Further  integrative  genomics 
attempts to boost statistical power to 
identify  genetic  interactions  in 
GWAS included the use of pairs of 
SNP markers whose combined state 
was associated with the phenotype79. 
A bi-clustering method was used to 
group  SNP-SNP  interactions  into 
interactions between larger genomic 
regions,  i.e.,  reinforced  by 
interactions  involving  multiple 
SNPs, which were then projected on 
a  protein-protein  interaction  network,  see  Fig.  3.   The  analysis  showed  that  genetic 
interactions uncovered by GWAS were strongly enriched within and between complexes 
of protein-protein interaction.  A novel discovery from this GWAS-based method was 
that  the  INO80  chromatin  remodeling  complex  has  functional  links  to  transcription 
elongation  via  RNA polymerase  II  and vacuolar  protein  degradation.  Finally,  related 
approaches were developed for using prior knowledge to infer epistatic interactions from 
Figure  3. Genetic  networks  extracted  GWAS  elucidate 
pathway architecture. (A) A global map of the top GWAS 
genetic  interactions  between  protein  interaction 
complexes.  Each node represents  a protein complex and 
each interaction represents a significant number of genetic 
interactions. Node sizes are proportional to the number of 
proteins in the complex. (B,C) Two specific examples of 
protein  complexes  spanned by  dense  bundles  of  genetic 
interactions mined from the GWAS data. 
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GWAS data38.
 Genetical Genomics: Another class of integrative genomics approaches used to reverse 
engineer  regulatory  networks  is  systems  genetics,  a  broad  class  of  approaches  that 
integrate naturally occurring genetic variation with large-scale molecular phenotypic and 
higher order phenotype data (e.g., clinical trait data) to infer causal relationships among 
genes and between genes and phenotypes of interest.   Variations in DNA can directly 
affect protein function, transcript structure (alternative splicing), transcription levels of 
sense  strand  of  genes,  antisense  transcription  of  genes,  non-coding  transcript  levels, 
among other molecular phenotypes.  These “cis” changes in gene activity can in turn 
affect  the  states  of  many  other  genes  (in  “trans”),  so  that  they  can  be  viewed  as 
perturbations in the same way as artificial perturbations (e.g.,  gene knockouts, siRNA 
knockdown, transgenics, and chemical perturbations) commonly employed in biology to 
establish causal relationships.  However, naturally occurring DNA variation is a more 
relevant perturbation source given common forms of human disease are caused by such 
variation, and so understanding causality in the context of such variation is perhaps the 
most relevant context in understanding disease, how best to assess disease risk, how best 
to track disease progression, and how best to treat disease. 
It  is  now well  established that  variations  in DNA can be used to infer causal 
relationships  among  molecular  phenotypes  and  reconstruct  entire  gene  networks  by 
systematically  assessing  the  impact  of  DNA  variation  on  gene  expression,  protein 
expression,  metabolite  expression,  and the interactions  between proteins,  proteins  and 
DNA, and proteins and metabolites.  The construction of large-scale gene networks can 
elucidate  subnetworks  comprised  of  highly  interconnected  sets  of  genes  driven  by 
common  genetic  factors  that  in  turn  associate  with  disease  (or  other  phenotypes  of 
interest), without depending on known pathway information (i.e., completely data driven; 
objective).  As an example, Zhong et al.  identified a subnetwork from a large-scale gene 
network constructed from islets isolated from a population of mice segregating a type 2 
diabetes phenotype, where genetic loci in this population associated with t2d were very 
strongly enriched for associating with genes in this network.  The integration of these 
data were then used to show that over half of the genes in this population supported as 
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causal for t2d were located in this single subnetwork.  SNPs in human populations that 
were associated with the genes comprising this mouse-derived t2d network were then 
observed to be greater than 8 times enriched for SNPs that associate with t2d in GWAS 
(one of the most striking pathway enrichments published to date for a common human 
disease).  Interestingly, no similar enrichments were observed in using known pathways 
defined in the GO and KEGG databases (Zhong et al. AJHG paper). 
Along  similar  lines,  module  networks  approaches45 were  extended  to  identify 
genetic  determinants  of  genetic  module differential  regulation80 as  well  as to  identify 
genetic alteration causally related to the presentation of tumor phenotypes81. 
Regulatory Network Analysis: Causal regulatory networks have also been successful in 
the inference of disease-related genes that have been experimentally validated. In these 
networks, similar to networks linking genetic variants with regulation,  interactions are 
directed (i.e.  causal)  rather than undirected as in protein-protein interaction networks. 
Thus, if the regulatory network is sufficiently accurate and comprehensive one may use it 
to traverse back the regulatory event to identify the regulators that are most likely to have 
produced the specific genetic profile (e.g. gene expression signature) within a specific 
disease-related  phenotype.  This  method  was  originally  proposed  for  networks 
reconstructed from DNA binding signatures of transcription factors, without experimental 
validation82.  More  recently,  these  Master  Regulator  genes  were  inferred  and 
experimentally validated both in disease, for human high-grade glioma54, and in normal 
physiologic processes, for formation of the germinal center15. For instance, in high-grade 
glioma, the MARINa (Master Regulator Inference algorithm) was used to identify the 
key  transcription  factors  that  implement  the  gene  expression  signature  of  the 
mesenchymal subtype of the disease, associated with the worst prognosis. The analysis 
identified  two genes,  C/EBP (including  the  C/EBPβ and δ  subunits)  and STAT3,  as 
master regulators. Ectopic expression of both genes, but not of each gene in isolation, 
was sufficient to reprogram neural stem cells along an aberrant mesenchymal lineage. 
Co-silencing in high-grade glioma lines, but not silencing of either gene in isolation, was 
sufficient  to  abrogate  the  mesenchymal  phenotype  and  tumorigenesis  in  vivo.  Direct 
exploration of GWAS data from the TCGA study on Glioblastoma in the context of genes 
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upstream of  these  master  regulators  has  identified  genetic  alterations  responsible  for 
virtually  100%  of  the  most  aggressive  high-grade  glioma,  including  the  focal 
amplification of C/EBPδ gene in ~20% of the mesenchymal cases. 
Diseaseome Approaches: Generalizing from pathways, sets of related genes, transcripts, 
and proteins  are  well  known to follow prescribed programs in the context  of human 
diseases.  Thus, another approach for the analysis of data from genome-wide association 
studies is by exploiting prior biological knowledge on the similarities or dissimilarities 
across diseases.
For  example,  while  there  is  widespread  belief  that  the  immune  system  is 
implicated in a variety of pathophysiological  phenotypes, suggesting that autoimmune 
disorders may share causal genetic variants with them, there are also notable differences 
across  these  disorders.   For  example,  the  G  allele  of  the  rs2076530  polymorphism 
BTNL2 (butyrophilin-like 2, a MHC class II associated gene) is more frequent among 
patients with Type 1 Diabetes and Rheumatoid Arthritis than in healthy controls, while 
the A allele was more frequent in patients with Systemic Lupus Erythematosus than in 
healthy individuals83.  One way to exploit these disease-relations is to study the results of 
multiple GWAS with each other, to find SNPs commonly predisposing to the entire set of 
diseases,  or  more  interestingly  find  SNPs  predisposing  to  some  in  the  set,  while 
significantly protecting against the others.  Such “toggleSNPs” could be used to shed 
light on the molecular details in actual human disease incidence, a key advantage over 
disease studies in animal models84.
Phenotype canalization: In many diseases but especially in cancer, there is evidence of 
an apparent paradox. While the number of distinct genetic and epigenetic alterations, both 
germline and somatic, associated with the etiology of the disease is generally large, the 
number of distinct molecular subtypes arising from the analysis of molecular profile data 
is significantly smaller. For instance, in high-grade glioma, dozens of genetic alterations 
have been reported85 and yet there are only three or four distinct molecular subtypes. If 
both observations  are  true,  then one has to  conjecture  the existence of an integrative 
logic,  usually  at  the  transcriptional  regulation  level,  that  canalizes  signals  from  the 
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complex spectrum of genetic and epigenetic alterations into a few molecular phenotypes, 
representing aberrant yet highly stable developmental states of the cell. The existence of 
this integrative logic has been elucidated in several tumors, including lymphomas71 and 
high-grade gliomas54. These observations suggest yet another approach to NBAS, based 
on the identification of the regulatory modules that control the disease subtype signatures 
followed by interrogations of pathways directly upstream of these modules as well as by 
association of genetic alterations in the tissue sample with the activity of these modules, 
for instance using the mutual information, , between the presence of a specific 
alteration Ax and module activity M. These types of approaches may significantly reduce 
the number of hypotheses that may need to be tested and increase the specificity of the 
molecular link from alteration→cellular-phenotype  to alteration→molecular-phenotype, 
the latter being far less prone to assessment errors.
A NEED TO REVIEW HOW WE WORK TOGETHER
The  power  to  build  better  maps  of  disease  in  the  post-GWAS era  clearly  leverages 
emerging “omics” technologies that will benefit from collecting data from large samples 
of patients over multiple  intervals of time. Most of the historic studies that drive our 
current understanding of diseases have been performed by single institutions often with 
the primary goal of taking data to build models that are then communicated as the results 
and conclusions  conveyed by citable  scientific  articles.  This  current  process does not 
assume that most data might be more useful if it could be accessed by others to build 
further models and hypotheses, beyond those envisioned by the original scientist. In fact, 
the absence of a culture of appropriate data sharing in the life and biomedical sciences is 
perhaps  the  single  greatest  impediment  to  the  rapid  development  of  the  integrative 
techniques  described above. For instance,  GWAS data will  no longer be sufficient  in 
isolation to understand the complexity of disease and how best to predict and treat it, but 
instead will need to be paired with additional molecular profile data as well as with data 
that  may be used to  dissect  the underlying  regulatory  model  for  the  specific  cellular 
context of interest.
Even though genomic data is robust and may be successfully used across a wide 
range of analyses, most investigators involved in clinical genomic studies hold the data 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
11
.5
73
2.
1 
: P
os
te
d 
24
 F
eb
 2
01
1
hostage for fear of missing out on the opportunity to extract the last bit of publishable 
value from it. The net result is that 80% of data is never published and more importantly 
never shared. Although journals and funding agencies have started to request that data be 
made publically accessible, investigators rarely provide their data in a format that is easy 
to access by others to reproduce their original ideas, or even better to explore new models 
or  new  hypotheses  not  originally  contemplated.  Even  more  problematic,  the  review 
process may delay release of a critical dataset by years. This should be seen as akin to 
living in a 21st century scientific “hunter-gatherer” society.
For  clinical  scientists  and  network  biologists  to  evolve  toward  a  more  generative 
scientific society, where open access to useful data and models is the rule, both technical 
and cultural changes are necessary. Most data is not annotated in ways that allow others 
to  easily  integrate  it  or  even  interpret  it.  Yet  other  fields  such  as  electronics  and 
economics live in a world of fully shareable standards for data exchange. This integration 
will  thus  require  new  standards  and  annotations  that  have  become  a  part  of  other 
scientific disciplines such as astronomers, physicists and climatologists who work with 
large datasets. The cultural barriers to evolving data sharing involve re-examining current 
reward structures for career advancement and peer recognition that are based on being a 
first or last author, and the need to own intellectual property around biologic insights. We 
need to transition to a workplace where scientists are rewarded for their insights, such as 
the proposing of new disease models, so that they can occur much earlier in the process 
of working with clinical/genomic data sets.
One example  of  piloting  the  advantages  of  sharing data,  models,  and tools  is 
called “The Federation”. In the summer of 2010 five groups: Sage Bionetworks, the Butte 
lab, the Califano lab, the Ideker lab, and the Schadt lab decided to test the mechanics of 
data  sharing  by  jointly  working  on projects  in  aging,  diabetes,  and cancer  based  on 
predefined rules  on data  access  and data  sharing.  Federation  rules  imply that  anyone 
interested in data,  tools,  and models produced by any of the five groups would have 
access  to  these  pooled  resources  and  would  implicitly  respect  publication  rights  by 
including data producers in their  manuscripts  and by notifying each other of pending 
manuscripts using this data. More importantly, it was set up so that disease models would 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
11
.5
73
2.
1 
: P
os
te
d 
24
 F
eb
 2
01
1
be built by teams dynamically formed for the projects in an environment usually only 
seen  for  “open  source”  software  projects.  Multiple  early  experiments  such  as  The 
Federation will be needed to aid in the development of the type of governance rules and 
processes required to facilitate the sharing in a laboratory environment needed to build 
the generative disease maps possible in the NBAS and PWAS worlds that follow the 
large national scale effort in GWAS.
Conclusions
Regulatory networks are emerging as powerful integrative frameworks to understand and 
interpret the role of genetics and epigenetics in disease predisposition and etiology. By 
providing the backbone of molecular interactions through which signals are transduced 
and  gene  expression  is  regulated,  they  dramatically  limit  the  search  space  of  allele 
variants and alterations that can be causally linked to the presentation of a phenotype. In 
addition,  by  providing  accurate  regulatory  models  of  the  cellular  machinery  that 
integrates  signals that  are  dysregulated  in  disease,  they yield valuable  hypotheses  for 
diagnostic and prognostic biomarkers, for therapeutic targets, and for the understanding 
of context-specific synthetic lethality. 
For regulatory networks to yield their full potential, however, we must understand 
their variability across cellular context, their dependence on the genetic and epigenetic 
layer,  and their  dynamics  over  time.  The latter  is  particularly  important  for  diseases 
where the underlying cellular pathophysiology cannot be considered to be close to steady 
state, such as metabolic and neurological diseases. 
Surprisingly,  even  rough  regulatory  models  that  are  largely  inaccurate  and 
incomplete are starting to show significant value in dissecting the genetics of disease. 
Thus, we expect that as these models progress and become better able to deal with the 
dynamic,  cell  context-specific  nature  of  biological  process  regulation,  they  will 
dramatically increase their ability to yield key insight into both normal cell physiology 
and its dysregulation in disease. We herald network reverse-engineering and interrogation 
as one of the most critical challenges of quantitative biology. 
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
11
.5
73
2.
1 
: P
os
te
d 
24
 F
eb
 2
01
1
References:
1. Stranger BE, Stahl EA, Raj T. Progress and Promise of Genome-wide Association 
Studies for Human Complex Trait Genetics. Genetics 2010.
2. Kraft P, Hunter DJ. Genetic Risk Prediction -- Are We There Yet? N Engl J Med 
2009.
3. Hardy J, Singleton A. Genomewide Association Studies and Human Disease. N 
Engl J Med 2009:NEJMra0808700.
4. Goldstein  DB. Common Genetic  Variation  and Human Traits.  N Engl  J  Med 
2009.
5. Zeggini E, Scott LJ, Saxena R, et al. Meta-analysis of genome-wide association 
data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. 
Nat Genet 2008;40:638-45.
6. Lyssenko V, Jonsson A, Almgren P, et al. Clinical risk factors, DNA variants, and 
the development of type 2 diabetes. N Engl J Med 2008;359:2220-32.
7. Altshuler D, Daly MJ, Lander ES. Genetic mapping in human disease. Science 
2008;322:881-8.
8. Manolio  TA,  Collins  FS,  Cox  NJ,  et  al.  Finding  the  missing  heritability  of 
complex diseases. Nature 2009;461:747-53.
9. Narayanan M, Vetta A, Schadt EE, Zhu J. Simultaneous clustering of multiple 
gene expression and physical interaction datasets. PLoS Comput Biol 2010;6:e1000742.
10. Stephens  PJ,  Greenman  CD,  Fu  B,  et  al.  Massive  Genomic  Rearrangement 
Acquired in a Single Catastrophic Event during Cancer Development. Cell 2011;144:27-
40.
11. Zhong  H,  Yang  X,  Kaplan  LM,  Molony  C,  Schadt  EE.  Integrating  pathway 
analysis and genetics of gene expression for genome-wide association studies. Am J Hum 
Genet 2010;86:581-91.
12. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a 
knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl 
Acad Sci U S A 2005;102:15545-50.
13. Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, Kanehisa M. KEGG: Kyoto 
Encyclopedia of Genes and Genomes. Nucleic Acids Res 1999;27:29-34.
14. Wang K, Li M, Hakonarson H. Analysing biological pathways in genome-wide 
association studies. Nat Rev Genet 2010;11:843-54.
15. Lefebvre  C,  Rajbhandari  P,  Alvarez  MJ,  et  al.  A  human  B-cell  interactome 
identifies MYB and FOXM1 as master regulators of proliferation in germinal centers. 
Mol Syst Biol 2010;6:377.
16. Wang  K,  Alvarez  MJ,  Bisikirska  BC,  et  al.  Dissecting  the  interface  between 
signaling  and  transcriptional  regulation  in  human  B  cells.  Pac  Symp  Biocomput 
2009:264-75.
17. Consortium  EP,  Birney  E,  Stamatoyannopoulos  JA,  et  al.  Identification  and 
analysis  of  functional  elements  in  1% of  the  human  genome  by  the  ENCODE pilot 
project. Nature 2007;447:799-816.
18. Margolin AA, Palomero T, Sumazin P, Califano A, Ferrando AA, Stolovitzky G. 
ChIP-on-chip significance analysis reveals large-scale binding and regulation by human 
transcription factor oncogenes. Proc Natl Acad Sci U S A 2009;106:244-9.
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
11
.5
73
2.
1 
: P
os
te
d 
24
 F
eb
 2
01
1
19. Ravasi  T,  Suzuki  H,  Cannistraci  CV,  et  al.  An  atlas  of  combinatorial 
transcriptional regulation in mouse and man. Cell 2010;140:744-52.
20. Rual JF, Venkatesan K, Hao T, et al. Towards a proteome-scale map of the human 
protein-protein interaction network. Nature 2005;437:1173-8.
21. Chen Y, Zhu J, Lum PY, et al. Variations in DNA elucidate molecular networks 
that cause disease. Nature 2008;452:429-35.
22. Emilsson V, Thorleifsson G, Zhang B, et al. Genetics of gene expression and its 
effect on disease. Nature 2008;452:423-8.
23. Schadt EE, Lamb J, Yang X, et al.  An integrative genomics approach to infer 
causal associations between gene expression and disease. Nat Genet 2005;37:710-7.
24. Yang X, Deignan JL, Qi H, et al. Validation of candidate causal genes for obesity 
that affect shared metabolic pathways and networks. Nat Genet 2009.
25. Zhu J, Zhang B, Smith EN, et al. Integrating large-scale functional genomic data 
to dissect the complexity of yeast regulatory networks. Nat Genet 2008;40:854-61.
26. Zhong H, Beaulaurier J, Lum PY, et al. Liver and adipose expression associated 
SNPs are enriched for association to type 2 diabetes. PLoS Genet 2010;6:e1000932.
27. Kinzler  KW,  Vogelstein  B.  Landscaping  the  cancer  terrain.  Science 
1998;280:1036-7.
28. Dobrin  R,  Zhu J,  Molony C,  et  al.  Multi-tissue  coexpression  networks  reveal 
unexpected subnetworks associated with disease. Genome Biol 2009;10:R55.
29. Keller MP, Choi Y, Wang P, et al. A gene expression network model of type 2 
diabetes  links cell  cycle  regulation in islets  with diabetes  susceptibility.  Genome Res 
2008;18:706-16.
30. Ferron M, Wei J, Yoshizawa T, et al. Insulin signaling in osteoblasts integrates 
bone remodeling and energy metabolism. Cell 2010;142:296-308.
31. Schadt  EE.  Molecular  networks  as  sensors  and  drivers  of  common  human 
diseases. Nature 2009;461:218-23.
32. Basso K, Margolin  AA, Stolovitzky G,  Klein  U, Dalla-Favera R,  Califano A. 
Reverse engineering of regulatory networks in human B cells. Nat Genet 2005;37:382-
90.
33. Wang  K,  Saito  M,  Bisikirska  BC,  et  al.  Genome-wide  identification  of  post-
translational modulators of transcription factor activity in human B cells. Nat Biotechnol 
2009;27:829-39.
34. Mani KM, Lefebvre C, Wang K, et al. A systems biology approach to prediction 
of oncogenes and molecular  perturbation targets  in B-cell  lymphomas. Mol Syst Biol 
2008;4:169.
35. Luscombe  NM,  Babu  MM,  Yu  H,  Snyder  M,  Teichmann  SA,  Gerstein  M. 
Genomic  analysis  of  regulatory  network  dynamics  reveals  large  topological  changes. 
Nature 2004;431:308-12.
36. Bandyopadhyay  S,  Mehta  M,  Kuo D,  et  al.  Rewiring  of  genetic  networks  in 
response to DNA damage. Science 2010;330:1385-9.
37. Pan  W.  Network-based  model  weighting  to  detect  multiple  loci  influencing 
complex diseases. Hum Genet 2008;124:225-34.
38. Chen  GK,  Thomas  DC.  Using biological  knowledge  to  discover  higher  order 
interactions in genetic association studies. Genet Epidemiol 2010;34:863-78.
39. Calvano SE, Xiao W, Richards DR, et al. A network-based analysis of systemic 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
11
.5
73
2.
1 
: P
os
te
d 
24
 F
eb
 2
01
1
inflammation in humans. Nature 2005;437:1032-7.
40. Elkon  R,  Rashi-Elkeles  S,  Lerenthal  Y,  et  al.  Dissection  of  a  DNA-damage-
induced transcriptional network using a combination of microarrays, RNA interference 
and computational promoter analysis. Genome Biol 2005;6:R43.
41. Sachs  K,  Perez  O,  Pe'er  D,  Lauffenburger  DA,  Nolan  GP.  Causal  protein-
signaling networks derived from multiparameter single-cell data. Science 2005;308:523-
9.
42. Quayle  AP,  Siddiqui  AS,  Jones  SJ.  Perturbation  of  interaction  networks  for 
application to cancer therapy. Cancer Inform 2007;5:45-65.
43. Birtwistle  MR,  Hatakeyama  M,  Yumoto  N,  Ogunnaike  BA,  Hoek  JB, 
Kholodenko  BN.  Ligand-dependent  responses  of  the  ErbB  signaling  network: 
experimental and modeling analyses. Mol Syst Biol 2007;3:144.
44. Nelander S, Wang W, Nilsson B, et al. Models from experiments: combinatorial 
drug perturbations of cancer cells. Mol Syst Biol 2008;4:216.
45. Segal  E,  Shapira  M, Regev A,  et  al.  Module  networks:  identifying  regulatory 
modules and their  condition-specific  regulators  from gene expression data.  Nat Genet 
2003;34:166-76.
46. Friedman  N.  Inferring  cellular  networks  using  probabilistic  graphical  models. 
Science 2004;303:799-805.
47. Gardner TS, di Bernardo D, Lorenz D, Collins JJ. Inferring genetic networks and 
identifying compound mode of action via expression profiling. Science 2003;301:102-5.
48. Linding  R,  Jensen  LJ,  Ostheimer  GJ,  et  al.  Systematic  discovery  of  in  vivo 
phosphorylation networks. Cell 2007;129:1415-26.
49. Bandyopadhyay  S,  Chiang  CY,  Srivastava  J,  et  al.  A  human  MAP  kinase 
interactome. Nat Methods 2010;7:801-5.
50. Huang Y,  Zou Q,  Song H,  et  al.  A study of  miRNAs targets  prediction  and 
experimental validation. Protein Cell 2010;1:979-86.
51. Shlomi  T,  Cabili  MN,  Herrgard  MJ,  Palsson  BO,  Ruppin  E.  Network-based 
prediction of human tissue-specific metabolism. Nat Biotechnol 2008;26:1003-10.
52. Zhu  J,  Lum  PY,  Lamb  J,  et  al.  An  integrative  genomics  approach  to  the 
reconstruction  of  gene  networks  in  segregating  populations.  Cytogenet  Genome  Res 
2004;105:363-74.
53. Yang X, Deignan JL, Qi H, et al. Validation of candidate causal genes for obesity 
that affect shared metabolic pathways and networks. Nat Genet 2009;41:415-23.
54. Carro  MS,  Lim  WK,  Alvarez  MJ,  et  al.  The  transcriptional  network  for 
mesenchymal transformation of brain tumours. Nature 2010;463:318-25.
55. Zhao X, D DA, Lim WK, et al. The N-Myc-DLL3 cascade is suppressed by the 
ubiquitin  ligase  Huwe1  to  inhibit  proliferation  and  promote  neurogenesis  in  the 
developing brain. Dev Cell 2009;17:210-21.
56. Yang X, Peterson L, Thieringer R, et al. Identification and validation of genes 
affecting aortic lesions in mice. J Clin Invest 2010;120:2414-22.
57. Konig R, Stertz S, Zhou Y, et al. Human host factors required for influenza virus 
replication. Nature 2010;463:813-7.
58. Jansen  R,  Yu  H,  Greenbaum  D,  et  al.  A  Bayesian  networks  approach  for 
predicting protein-protein interactions from genomic data. Science 2003;302:449-53.
59. Sharan R, Suthram S, Kelley RM, et al. Conserved patterns of protein interaction 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
11
.5
73
2.
1 
: P
os
te
d 
24
 F
eb
 2
01
1
in multiple species. Proc Natl Acad Sci U S A 2005;102:1974-9.
60. Lamb  J,  Crawford  ED,  Peck  D,  et  al.  The  Connectivity  Map:  using  gene-
expression  signatures  to  connect  small  molecules,  genes,  and  disease.  Science 
2006;313:1929-35.
61. Wang W, Cherry JM, Botstein D, Li H. A systematic approach to reconstructing 
transcription  networks  in  Saccharomycescerevisiae.  Proc  Natl  Acad  Sci  U  S  A 
2002;99:16893-8.
62. Pe'er D, Regev A, Elidan G, Friedman N. Inferring subnetworks from perturbed 
expression profiles. Bioinformatics 2001;17 Suppl 1:S215-24.
63. di Bernardo D, Thompson MJ, Gardner TS, et al. Chemogenomic profiling on a 
genome-wide  scale  using  reverse-engineered  gene  networks.  Nat  Biotechnol 
2005;23:377-83.
64. Chen  BJ,  Causton  HC,  Mancenido  D,  Goddard  NL,  Perlstein  EO,  Pe'er  D. 
Harnessing gene expression to identify the genetic basis of drug resistance. Mol Syst Biol 
2009;5:310.
65. Jia J, Zhu F, Ma X, Cao Z, Li Y, Chen YZ. Mechanisms of drug combinations:  
interaction and network perspectives. Nat Rev Drug Discov 2009;8:111-28.
66. Chautard E, Thierry-Mieg N, Ricard-Blum S. Interaction networks: from protein 
functions to drug discovery. A review. Pathol Biol (Paris) 2009;57:324-33.
67. Xie  L,  Li  J,  Bourne  PE.  Drug  discovery  using  chemical  systems  biology: 
identification of the protein-ligand binding network to explain the side effects of CETP 
inhibitors. PLoS Comput Biol 2009;5:e1000387.
68. Berger SI, Iyengar R. Network analyses in systems pharmacology. Bioinformatics 
2009;25:2466-72.
69. Iadevaia S, Lu Y, Morales FC, Mills GB, Ram PT. Identification of optimal drug 
combinations  targeting  cellular  networks:  integrating  phospho-proteomics  and 
computational network analysis. Cancer Res 2010;70:6704-14.
70. Pandey G, Zhang B, Chang AN, et al. An integrative multi-network and multi-
classifier approach to predict genetic interactions. PLoS Comput Biol 2010;6.
71. Compagno  M,  Lim WK,  Grunn  A,  et  al.  Mutations  of  multiple  genes  cause 
deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009;459:717-21.
72. Feldman  I,  Rzhetsky  A,  Vitkup  D.  Network  properties  of  genes  harboring 
inherited disease mutations. Proc Natl Acad Sci U S A 2008;105:4323-8.
73. Ideker  T,  Ozier  O,  Schwikowski  B,  Siegel  AF.  Discovering  regulatory  and 
signalling  circuits  in  molecular  interaction  networks.  Bioinformatics  2002;18  Suppl 
1:S233-40.
74. Zien A, Kuffner R, Zimmer R, Lengauer T. Analysis of gene expression data with 
pathway scores. Proc Int Conf Intell Syst Mol Biol 2000;8:407-17.
75. Faust  K,  Dupont  P,  Callut  J,  van  Helden  J.  Pathway  discovery  in  metabolic 
networks by subgraph extraction. Bioinformatics 2010;26:1211-8.
76. Ulitsky I, Krishnamurthy A, Karp RM, Shamir R. DEGAS: de novo discovery of 
dysregulated pathways in human diseases. PLoS ONE 2010;5:e13367.
77. Lage K, Karlberg EO, Storling ZM, et al. A human phenome-interactome network 
of protein complexes implicated in genetic disorders. Nat Biotechnol 2007;25:309-16.
78. Jia P, Zheng S, Long J, Zheng W, Zhao Z. dmGWAS: dense module searching for 
genome-wide association studies in protein-protein interaction networks. Bioinformatics 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
11
.5
73
2.
1 
: P
os
te
d 
24
 F
eb
 2
01
1
2011;27:95-102.
79. Hannum G, Srivas R, Guenole A, et al. Genome-wide association data reveal a 
global  map  of  genetic  interactions  among  protein  complexes.  PLoS  Genet 
2009;5:e1000782.
80. Lee  SI,  Pe'er  D,  Dudley  AM,  Church  GM,  Koller  D.  Identifying  regulatory 
mechanisms using individual variation reveals key role for chromatin modification. Proc 
Natl Acad Sci U S A 2006;103:14062-7.
81. Akavia UD, Litvin O, Kim J, et al. An integrated approach to uncover drivers of 
cancer. Cell 2010;143:1005-17.
82. Rhodes  DR,  Kalyana-Sundaram  S,  Mahavisno  V,  Barrette  TR,  Ghosh  D, 
Chinnaiyan AM. Mining for regulatory programs in the cancer transcriptome. Nat Genet 
2005;37:579-83.
83. Orozco  G,  Eerligh  P,  Sanchez  E,  et  al.  Analysis  of  a  functional  BTNL2 
polymorphism in type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosus. 
Hum Immunol 2005;66:1235-41.
84. Sirota  M,  Schaub  MA,  Batzoglou  S,  Robinson  WH,  Butte  AJ.  Autoimmune 
disease  classification  by  inverse  association  with  SNP  alleles.  PLoS  Genet 
2009;5:e1000792.
85. TCGA-Consortium.  Comprehensive  genomic  characterization  defines  human 
glioblastoma genes and core pathways. Nature 2008;455:1061-8.
86. Phillips  HS,  Kharbanda S,  Chen R,  et  al.  Molecular  subclasses  of  high-grade 
glioma predict prognosis, delineate a pattern of disease progression, and resemble stages 
in neurogenesis. Cancer Cell 2006;9:157-73.
87. Verhaak  RG,  Hoadley  KA,  Purdom  E,  et  al.  Integrated  genomic  analysis 
identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in 
PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
11
.5
73
2.
1 
: P
os
te
d 
24
 F
eb
 2
01
1
